Chronic obstructive pulmonary disease remains a leading cause of morbidity and mortality worldwide, significantly affecting healthcare systems and patients’ quality of life, while real-world evidence supporting the effectiveness of fixed triple inhaled therapy remains limited despite its established benefits in clinical trials. To address this gap, a real-world study evaluated the effectiveness of fixed triple combinations of inhaled corticosteroids, long-acting β2-agonists, and long-acting muscarinic antagonists in improving clinical outcomes among 1,336 patients with moderate to severe COPD.
The study found that patients had a baseline average COPD Assessment Test (CAT) score of 20.4 and an average FEV1 of 52.3%, with most participants reporting limitations in one or more dimensions of the EQ-5D-3L quality-of-life assessment and an average visual analogue scale (VAS) score of 59.1.…
